6996.HK

Premier Integrated Platform in APAC to Develop Innovative Therapies for Oncology Antengene Corporation Limited Successfully Listed on Main Board of SEHK

Life sciences, Biotechnology, Articles, Biopharmaceutical, Pharmaceutical industry, Pharmacy
星期五, 十一月 20, 2020 - 6:15am

The offer shares initially offered under the International Offering have also been over-subscribed by approximately 13.5 times.

Key Points: 
  • The offer shares initially offered under the International Offering have also been over-subscribed by approximately 13.5 times.
  • Antengene Corporation Limited is a clinical-stage APAC biopharmaceutical company focused on innovative oncology medicines.
  • At Antengene, we focus on developing drug candidates with novel targets or MoAs and first-in-class potential to address significant unmet medical needs.
  • The vision of Antengene is to "Treat Patients Beyond Borders" through research, development and commercialization of first-in-class/best-in-class therapeutics.